<DOC>
	<DOC>NCT00162110</DOC>
	<brief_summary>This is a Phase II open-label trial evaluating the efficacy, and safety of Erbitux in patients with mucinous gastrointestinal adenocarcinoma involving the peritoneal surface.</brief_summary>
	<brief_title>A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Able to take care of self. Out of bed less than 50% of the day Absolute neutrophil count &gt;=1,500 Platelet count &gt;=100,000 Total bilirubin count &lt;=1.5 times the upper limit of normal Prior epidermal growth factor receptor antibody Prior treatment with Erbitux Other cancers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>